Cartilage Health News
-
What Are D-Glucosamines?
Glucosamine is a natural component of cartilage and is widely used as an over-the-counter nutritional supplement to reduce the pain and cartilage loss of osteoarthritis. Glucosamine is usually taken in combination with chondroitin, which is a glycosaminoglycan that also exists in cartilage.Glucosamine is an amino sugar and an important molecule in the biochemical pathway of glycosylated protein ...
-
Hyalex Orthopaedics appoints Carl Vause, orthopaedic industry veteran, as Chief Executive Officer and President; Names Mike Hawkins, PhD, Chief Technical Officer
Hyalex Orthopaedics, a privately-held medical device company developing transformational cartilage biomimetic products, today announced the appointment of Carl Vause as its new chief executive officer and president. Mr. Vause, who succeeds Hyalex’s interim president, Michael Hawkins, Ph.D., has also been appointed to the company’s board of directors. Additionally, Dr. Hawkins has ...
-
Healx pledges $25,000 to AKU Society patient registry campaign
Patient registries play a critical role in the development of treatments for rare diseases – 95% of which are still without an approved therapy today. Knowledge limitations around rare conditions are a huge barrier to treatment development and are compounded by the fact that rare disease patient populations are often small and geographically dispersed. Registries collect information ...
By Healx Ltd.
-
Agreement signed with TELA Bio Inc
Next Science Limited (ASX:NXS) (Next Science) is pleased to announce that it has signed a multi-year distribution agreement with NASDAQ listed medical technology company, TELA Bio, Inc in relation to the supply of a white labelled version of Next Science’s proprietary XPERIENCETM No Rinse Antimicrobial Solution. The new agreement grants TELA Bio, Inc exclusive rights across the US plastic ...
-
Hyalex receives FDA Breakthrough Device Designation for novel HYALEX Cartilage System
Hyalex Orthopaedics, Inc., announced that the HYALEX Cartilage System has been granted Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA). The HYALEX Cartilage System is intended to repair cartilage defects and restore function for patients with loss of knee articular cartilage and bone requiring surgery. Hyalex is currently in the pre-clinical stage of development ...
-
Philip Morris International and TissUse develop a human aerosol test platform to emulate the entire human respiratory tract
PMI and TissUse have signed a collaboration agreement to utilize PMI’s InHALES technology in combination with TissUse’s proprietary Multi-Organ-Chip (MOC) platform to enable inhalation exposure of functional human tissues in homeostasis at minute scale in vitro. The two partners will develop a highly innovative integrated human aerosol test platform that emulates the entire human ...
By TissUse GmbH
-
KiOmed Pharma and moveUP Partner to Develop and Market a Companion Healthcare Application for Personalised Treatment of Osteoarthritis
Belgian biotech company KiOmed Pharma and digital therapeutics company moveUP are pleased to announce the signature of an exclusive agreement for the development and licensing of a unique mobile health companion application dedicated to personalised conservative intra-articular treatment for patients suffering from osteoarthritis. This application is to be developed by moveUP, while exclusive ...
-
KiOmed Pharma reports promising long-term results in a new European multi centric survey Treatment of Advanced Knee OsteoArthritis
KiOmed Pharma, an innovative Belgian biotech company, has reported positive safety and efficacy outcomes following the treatment of nearly 80 patients suffering from Knee OsteoArthritis (OA). This European Healthcare Professional (HCP) survey yielded a global long-term improvement of OA symptoms and shows preliminary evidence of improved outcomes in patients with advanced stage OA. ‘This ...
-
Locate Bio’s Chondro3 Granted FDA Breakthrough Device Designation
The Company’s second FDA Breakthrough Device designation granted in 2021 Locate Bio, an orthobiologics focused regenerative medicine company, is pleased to announce that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device designation to Chondro3, currently in development as a biomimetic graft for osteochondral lesions. The FDA Breakthrough Device Program is designed ...
-
Moebius Medical Announces Dosing of First Patient in Global Phase IIb Clinical Trial of MM-II, a Novel Treatment for Knee Osteoarthritis Pain
Global Phase IIb study to enrol approximately 312 patients, each of whom will receive one of three doses of MM-II or placebo Primary endpoint is a reduction in pain from baseline as measured by WOMAC A pain scale at 12 weeks Israel-based Moebius Medical today announced that the first patient has been dosed in its Phase IIb clinical trial of MM-II, a novel candidate for the treatment of pain ...
-
Moebius Medical Announces FDA Clearance of IND Application for Phase IIb Clinical Trial of MM-II, a Novel Treatment for Knee Osteoarthritis Pain
Treatment leverages proprietary liposomes and first-in-class mechanism-of-action to achieve significant, sustainable pain relief Phase IIb study expected to begin enrolling by year-end with initial top-line data anticipated in mid-2022 Israel-based Moebius Medical today announced that the US Food and Drug administration (FDA) has cleared their Investigational New Drug (IND) application to ...
-
BioPoly Orthopedic Resurfacing Products Enter North America
FORT WAYNE, IN – BioPoly, LLC has entered into an exclusive distribution agreement with Canada-based distributor, Verve Medical Products, Inc., to distribute the BioPoly® partial resurfacing family of products throughout Canada, with distribution initially taking place through the Canadian SAP. Verve Medical Products specializes in bringing medical-surgical products to Canada through ...
By BioPoly, LLC
-
Cytex Awarded CRP Award for First-In-Human Pilot Trial
Cytex is thrilled to announce the receipt of a Commercialization Readiness Pilot Program Award from the National Institute of Health entitled “Cartilage Regeneration with Tunable Inflammation Resistance.” The goal of this project is to prepare for and then conduct a First-In-Human pilot clinical trial that will test the safety of Cytex’s innovative hip implant. Cytex is ...
-
Cytex Awarded CRP Award for First-In-Human Pilot Trial
Cytex is thrilled to announce the receipt of a Commercialization Readiness Pilot Program Award from the National Institute of Health entitled “Cartilage Regeneration with Tunable Inflammation Resistance.” The goal of this project is to prepare for and then conduct a First-In-Human pilot clinical trial that will test the safety of Cytex’s innovative hip implant. Cytex is ...
-
Locate Bio acquires complementary late stage orthobiologics assets
Locate Bio, an orthobiologics focused regenerative medicine company, today announced the in-licencing of multiple late stage orthobiologics assets from RCSI University of Medicine and Health Sciences. The technologies developed by the RCSI Tissue Engineering Research Group have extensive pre-clinical and human data demonstrating their effectiveness in the treatment of both hard and soft tissues. ...
-
StemBioSys expands its human chondrocyte offerings
StemBioSys introduced a new culture system designed to help investigators grow human chondrocytes in vitro faster while retaining a natural phenotype. The kit is comprised of CELLvo™ Matrix, a cell-derived extracellular matrix that mimics the chondrocytes’ natural microenvironment, and CELLvo™ Human Articular Chondrocytes, a collection of human chondrocytes sourced from donors ...
-
KiOmed Pharma obtains CE mark and signs a License and Supply Agreement
KiOmed Pharma announces the granting of the CE mark for its first implantable product intended to treat osteoarthritis symptoms and the signing of a License and Supply Agreement with TRB Chemedica, a leading pharmaceutical and biotechnology company. KiOmed Pharma announces the granting of the CE mark for its first implantable product intended to treat osteoarthritis symptoms and the signing of a ...
-
Symic Bio Announces First Patient Enrolled in Osteoarthritis Phase 2b Study
SAN FRANCISCO, March 1, 2020 – Symic Bio, a biopharmaceutical company developing novel extracellular matrix targeting drugs, today announced that the first patient had been enrolled in its Phase 2b OA (osteoarthritis) study. The study, dubbed MODIFY3, is a doubleblinded, randomized controlled trial investigating Symic Bio’s DMOAD (disease-modifying OA drug) candidate, SB-061 vs. ...
-
BioPoly Granted Another US Patent
FORT WAYNE, IN – BioPoly LLC has announced that another U.S. patent has been granted for its innovative BioPoly® material, which is currently being used to replace damaged cartilage in joints. Where some of the other BioPoly patents address the design of the implants, this patent family focuses on the material itself. This most recent patent, regarding material derivatives, adds to the ...
By BioPoly, LLC
-
VIVAX BIO and 3D Bioprinting Solutions World’s First To Print Living Tissue in Space
VIVAX BIO, 3D Bioprinting Solutions biotechnology laboratory and INVITRO, a leading medical company, announced a successful completion of the first stage of the Magnetic 3D Bioprinter space experiment. On December 3, 2018, the Organ.Aut bioprinter was delivered to the ISS on board the Soyuz MS-11 manned spacecraft. For the first time on orbit, cosmonaut-researcher Oleg Kononenko printed human ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you